Přehled publikací členů laboratoře

1. Preparation of Tryptanthrin Derivates Bearing a Thiosemicarbazone Moiety to Inhibit SARS-CoV-2 Replication. Veselá K, Mělková Z; Abramenko N; Kejík Z; Kaplánek R; Dytrych P; Sinica A; Vozniuk O; Martásek P; Jakubek M. Separations 2023 10(2):73. doi: 10.3390/separations10020073. IF (2021): 3.344 


2. Vaccinia Virus Expressing Interferon Regulatory Factor 3 Induces Higher Protective Immune Responses against Lethal Poxvirus Challenge in Atopic Organism. Pilna H, Hajkova V, Knitlova J, Liskova J, Elsterova J, Melkova Z.*, Viruses. 2021 Oct 3;13(10):1986. doi: 10.3390/v13101986. IF (2020): 5.048 


3. Expression of TIM-3 on Plasmacytoid Dendritic Cells as a Predictive Biomarker of Decline in HIV-1 RNA Level during ART. Font-Haro A, Janovec V, Hofman T, Machala L, Jilich D, Melkova Z, Weber J, Trejbalova K, Hirsch I. Viruses 2018; 10(4), 154-167; doi: 10.3390/v10040154. IF (2018): 3.811 


4. Effects of heme degradation products on reactivation of latent HIV-1. Shankaran P, Madlenakova M, Hajkova V, Jilich D, Svobodova I, Horinek A, Fujikura Y, Melkova Z.*, Acta Virol. 2017;61(1):86-96. doi: 10.4149/av_2017_01_86. IF (2017): 0.696 


5. Current views on HIV-1 latency, persistence, and cure. Melkova Z.*, Shankaran P, Madlenakova M, Bodor J. Folia Microbiol (Praha). 2017 Jan;62(1):73-87. doi: 10.1007/s12223-016-0474-7. Review. IF (2017): 1.311 


6. Protein expression from unintegrated HIV-1 DNA introduces bias in primary in vitro latency models. Bonczkowski P, De Scheerder MA, Malatinkova E, Borch A, Melkova Z, Koenig R, De Spiegelaere W, Vandekerckhove L. Sci Rep. 2016 Dec 2;6:38329. doi: 10.1038/srep38329. IF (2016): 4.259 


7. Iron Overload Causes Alterations of E-cadherin in Liver. Fujikura Y, Krijt J, Povysil C, Melkova Z, Prikryl P, Vokurka M, Necas E. Folia Biol (Praha). 2016;62(3):95-102. IF (2016): 0.939 


8. Development of Eczema Vaccinatum in Atopic Mouse Models and Efficacy of MVA Vaccination against Lethal Poxviral Infection. Knitlova J, Hajkova V, Voska L, Elsterova J, Obrova B, Melkova Z.* PLoS One. 2014 Dec 8;9(12):e114374. IF (2014): 3.234 


9. Heme arginate potentiates latent HIV-1 reactivation while inhibiting the acute infection. Shankaran P, Vlkova L, Liskova J, Melkova Z.* Antiviral Res. 2011 Dec;92(3):434-46. Epub 2011 Oct 5. IF (2011): 4.301 


10. Apoptosis and necrosis in vaccinia virus-infected HeLa G and BSC-40 cells. Liskova J, Knitlova J, Honner R, Melkova Z.* Virus Res. 2011 Sep;160(1-2):40-50. Epub 2011 May 14. IF (2011): 2.941 


11. Ethacrynic and alpha-lipoic acids inhibit vaccinia virus late gene expression. Spisakova M., Cizek Z., Melkova Z. * Antiviral Research, 2009; 81(2): 156-165. IF (2009): 3.612 


12. The effect of nitric oxide on vaccinia virus-encoded ribonucleotide reductase. Fujikura Y., Kudlackova P., Vokurka M., Krijt J., Melkova Z. * Nitric Oxide, 2009; 20(2): 114-121. IF (2009): 2.506 


13. Lytic infection with vaccinia virus activates caspases in a Bcl-2-inhibitable manner. Kalbacova M., Spisakova M., Liskova J., Melkova Z. * Virus Reseaech, 2008; 135(1): 53-63. IF (2008): 2.429 


14. Inhibitory effects of Bcl-2 on mitochondrial respiration. Vrbacký M., Krijt J., Drahota Z., Mělková Z. * Physiology Research, 2003; 52(5): 545-554. IF(2003): 0.939 


15. Transient expression of wild-type and mutant glucocerebrosidases in hybrid vaccinia expression system. Hodanová K., Melková Z., Horowitz M., Hrebícek M. European Journal of Human Genetics, 2003;11(5): 369-374. IF(2003): 3.669 


16. Comparison of the effect of mitochondrial inhibitors in mitochondrial membrane potential in two different cell lines using flow cytometry and spectrofluorometry. Kalbácová M., Vrbacký M., Drahota Z., Melková Z. * Cytometry A, 2003; 52(2): 110-116. IF(2003): 2.095 


17. Vaccinia virus induces apoptosis of infected macrophages. Humlová Z., Vokurka M., Esteban M., Melková Z. * Journal of General Virology, 2002; 83(Pt 11): 2821-2832. IF(2002): 3.300 


18. Protooncogene Bcl-2 induces apoptosis in several cell lines. Kalbácová M., Vrbacký M., Humlová Z., Melková Z. * Folia Biologica, 2002; 48(1): 15-27. IF(2002): 0.615 


19. Detection of galectin-3 in tear fluid at disease states and immunohistochemical and lectin histochemical analysis in human corneal and conjunctival epithelium. Hrdlicková-Cela E., Plzák J., Smetana K Jr., Mělková Z., Kaltner H., Filipec M., Liu FT., Gabius HJ. British Journal of Ophthalmology, 2001; 85(11): 1336-1340. IF(2001): 1.942 


20. Vaccinia virus E3L protein is an inhibitor of the interferon (i.f.n.)-induced 2-5A synthetase enzyme. Rivas C., Gil J., Mělková Z., Díaz-Guerra M. Virology, 1998; 243(2): 406-414. IF(1998): 3.270 


21. Bcl-2 prevents nitric oxide-mediated apoptosis and poly(ADP-ribose) polymerase cleavage. Mělková Z. *, Lee SB., Rodriguez D., Esteban M.* FEBS Letters, 1997; 403(3): 273-278. IF(1997): 3.504 


22. Inhibition of vaccinia virus DNA replication by inducible expression of nitric oxide synthase. Mělková Z., Esteban M. Journal of Immunology, 1995; 155(12): 5711-5718. IF(1995): 7.412 


23. Interferon-gamma severaly inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Mělková Z., Esteban M. Virology, 1994; 198(2): 731-735. IF(1994): 3.879 


24. The interferon-induced double-stranded RNA-activated human p68 protein kinase potently inhibits protein synthesis in cultured cells. Lee SB., Melkova Z., Yan W., Williams BR., Hovanessian AG., Esteban M. Virology, 1993; 192(1): 380-385. IF(1993): 3.946 


25. First demonstration of porphyrins in the lacrimal glands: similarity to the Harderian gland. Hugo J., Vokurka M., Sanitrák J., Mělková Z., Janousek V. Biomedica Biochimica Acta, 1989; 48(9): K1-K4. IF(1989): 0.390 


26. Deriváty benzo(c)fluorenu. VIII. Využití indexů molekulové konektivity při studiu protinádorové aktivity skupiny derivátů benzo(c)fluorenu. [Derivatives of benzo(c)fluorene. VIII. Use of the index of molecular connectivity in the study of antineoplastic activity of a group of benzo(c)fluorene derivatives]. Mělková Z. * Cesk Farm., 1984; 33(3-4): 107-111

* Corresponding author

Patenty

1. Použití hem arginátu pro výrobu léčiva pro snížení velikosti latentního rezervoáru HIV-1 in vivo. Mělková Z, Jilich D, Madleňáková M, Martásek P. Patent No. 308873, udělen 17. června 2021, oznámeno 28.7.2021, Věstník č. 30/2021.


2. Použití hem arginátu pro výrobu léčiva pro léčbu infekce beta koronaviry. Mělková Z, Martásek Patent No. CZ308937, udělen 4. srpna 2021, oznámeno 15.9.2021, Věstník č. 37/2021.